Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

4.990 +0.620 (+14.19%)
Streaming Delayed Price Updated: 2:50 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
From Silence Therapeutics plc
Via Business Wire
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
The Analyst Landscape: 6 Takes On Silence Therapeutics
Via Benzinga
These stocks are moving in today's pre-market session
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Silence Therapeutics plc
Via Business Wire
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
Via Benzinga
Analyst Expectations For Silence Therapeutics's Future
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025. 
Via Talk Markets
Topics Stocks / Equities
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
From Silence Therapeutics plc
Via Business Wire
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Top 3 Health Care Stocks That May Explode In Q4
Via Benzinga
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing In Q4
Via Benzinga
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
Silence Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.